肺腺癌中99mTcO4-活性异常升高的病例报告
Elevated 99mTcO4- Activity in Adenocarcinoma of the Lung.
PubMed 文献 · Clin Nucl Med · 2021-01-01
一例73岁男性肺腺癌患者因骨转移评估行全身骨扫描时,误将99mTcO4-替代99mTc-MDP注射;显像显示已知肺部病灶处出现99mTcO4-活性异常浓聚。
要点
- 肺腺癌病灶可非特异性摄取99mTcO4-,导致显像异常浓聚。
- 骨扫描药物误用为99mTcO4-时,需注意肺部病灶的摄取可能被误判。
- 核医学药物注射前应严格核对,避免放射性药物错误使用。
核心结论
- 肺腺癌病灶可对99mTcO4-表现出异常升高的活性摄取。
研究设计与样本
- 病例报告:一例73岁男性肺腺癌患者因骨转移评估行全身骨扫描时误用99mTcO4-。
主要发现
- 全身骨扫描显像显示已知肺部病灶处出现99mTcO4-活性异常浓聚。
临床怎么用
- 核医学骨扫描注射前应严格核对放射性药物,避免误用99mTcO4-。
- 当99mTcO4-显像见肺部病灶浓聚时,需结合病史考虑肺腺癌摄取可能。
局限性
- 仅为单例病例报告,无法推广至所有肺腺癌患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 73-year-old man experienced chest tightness and shortness of breath for 9 months. Chest CT revealed a large right upper lobe mass. Pathology from CT-guided biopsy demonstrated poorly differentiated adenocarcinoma of the lung. Whole-body bone scan was acquired to evaluate possible bone metastasis. However, he was injected with 99mTcO4- erroneously instead of 99mTc-MDP. The images showed a focus of elevated activity of 99mTcO4- in the known lung lesion.
来源:Clin Nucl Med,查看原文。版权归原作者所有。
引用
- Ming H, Chen Y, Yu H, et al. Elevated 99mTcO4- Activity in Adenocarcinoma of the Lung. Clin Nucl Med. 2021. PMID: 33782284. doi:10.1097/RLU.0000000000003581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。